Antibiotic Resistance Market Size, Share & Trends Report

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (BSI, CDI, cUTI, cIAI), By Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae), By Drug Class, and Segment Forecasts, 2018 - 2025

Report ID: GVR-2-68038-663-9
Number of Pages: 120
Format: Electronic (PDF)

Historical Range:
Industry: Healthcare

Market Segmentation

Antibiotic Resistance Disease Outlook (Revenue, USD Billion, 2014 - 2025)
- Complicated Urinary Tract Infection (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Blood Stream Infections (BSI)
- Clostridium difficile infections (CDI)
- Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
- Community Acquired Bacterial Pneumonia (CABP)
Antibiotic Resistance Pathogen Outlook (Revenue, USD Billion, 2014 - 2025)
- Acinetobacter baumannii (Carbapenem-Resistant)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- E. coli/K. pneumoniae (Carbapenem-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
Antibiotic Resistance Drug Class Outlook (Revenue, USD Billion, 2014 - 2025)
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination
- Others
Antibiotic-resistance Regional Outlook (Revenue, USD Billion, 2014 - 2025)
- North America
  - North America Antibiotic Resistance Market, by Disease
    - Complicated Urinary Tract Infection (cUTI)
    - Complicated Intra-Abdominal Infections (cIAI)
    - Blood Stream Infections (BSI)
    - Clostridium difficile infections (CDI)
    - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    - Community Acquired Bacterial Pneumonia (CABP)
  - North America Antibiotic Resistance Market, by Pathogen
    - Acinetobacter baumannii (Carbapenem-Resistant)
    - Staphylococcus Aureus (Methicillin-Resistant)
    - Pseudomonas aeruginosa (Carbapenem-Resistant)
    - E. coli/K. pneumoniae (Carbapenem-Resistant)
    - Enterococcus faecium (Vancomycin-Resistant)
    - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    - Haemophilus Influenzae (Ampicillin-Resistant)
    - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  - North America Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Cephalosporins
    - Combination
    - Others
  - The U.S.
    - U.S. Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - U.S. Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - U.S. Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Canada
    - Canada Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Canada Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Canada Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
- Europe
  - Europe Antibiotic Resistance Market, by Disease
    - Complicated Urinary Tract Infection (cUTI)
    - Complicated Intra-Abdominal Infections (cIAI)
    - Blood Stream Infections (BSI)
    - Clostridium difficile infections (CDI)
    - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    - Community Acquired Bacterial Pneumonia (CABP)
  - Europe Antibiotic Resistance Market, by Pathogen
    - Acinetobacter baumannii (Carbapenem-Resistant)
    - Staphylococcus Aureus (Methicillin-Resistant)
    - Pseudomonas aeruginosa (Carbapenem-Resistant)
    - E. coli/K. pneumoniae (Carbapenem-Resistant)
    - Enterococcus faecium (Vancomycin-Resistant)
    - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    - Haemophilus Influenzae (Ampicillin-Resistant)
    - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  - Europe Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Cephalosporins
    - Combination
    - Others
  - The U.K.
    - U.K. Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - U.K. Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - U.K. Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Germany
    - Germany Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Germany Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Germany Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - France
    - France Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - France Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - France Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Italy
    - Italy Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Italy Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Italy Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Spain
    - Spain Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Spain Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Spain Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Belgium
    - Belgium Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Belgium Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Belgium Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Greece
    - Greece Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Greece Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Greece Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Portugal
    - Portugal Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Portugal Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Portugal Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
- Asia Pacific
  - Asia Pacific Antibiotic Resistance Market, by Disease
    - Complicated Urinary Tract Infection (cUTI)
    - Complicated Intra-Abdominal Infections (cIAI)
    - Blood Stream Infections (BSI)
    - Clostridium difficile infections (CDI)
    - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    - Community Acquired Bacterial Pneumonia (CABP)
  - Asia Pacific Antibiotic Resistance Market, by Pathogen
    - Acinetobacter baumannii (Carbapenem-Resistant)
    - Staphylococcus Aureus (Methicillin-Resistant)
    - Pseudomonas aeruginosa (Carbapenem-Resistant)
    - E. coli/K. pneumoniae (Carbapenem-Resistant)
    - Enterococcus faecium (Vancomycin-Resistant)
    - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    - Haemophilus Influenzae (Ampicillin-Resistant)
    - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  - Asia Pacific Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Cephalosporins
    - Combination
    - Others
  - Japan
    - Japan Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Japan Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Japan Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - China
    - China Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - China Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - China Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - India
    - India Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - India Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - India Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - South Korea
    - South Korea Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - South Korea Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - South Korea Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Australia
    - Australia Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Australia Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Australia Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Hong Kong
    - Hong Kong Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Hong Kong Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Hong Kong Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Singapore
    - Singapore Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Singapore Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Singapore Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Taiwan
    - Taiwan Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Taiwan Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Taiwan Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
- Latin America
  - Latin America Antibiotic Resistance Market, by Disease
    - Complicated Urinary Tract Infection (cUTI)
    - Complicated Intra-Abdominal Infections (cIAI)
    - Blood Stream Infections (BSI)
    - Clostridium difficile infections (CDI)
    - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    - Community Acquired Bacterial Pneumonia (CABP)
  - Latin America Antibiotic Resistance Market, by Pathogen
    - Acinetobacter baumannii (Carbapenem-Resistant)
    - Staphylococcus Aureus (Methicillin-Resistant)
    - Pseudomonas aeruginosa (Carbapenem-Resistant)
    - E. coli/K. pneumoniae (Carbapenem-Resistant)
    - Enterococcus faecium (Vancomycin-Resistant)
    - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    - Haemophilus Influenzae (Ampicillin-Resistant)
    - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  - Latin America Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Cephalosporins
    - Combination
    - Others
  - Brazil
    - Brazil Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Brazil Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Brazil Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Mexico
    - Mexico Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Mexico Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Mexico Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Argentina
    - Argentina Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Argentina Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Argentina Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
- Middle East and Africa
  - Middle East and Africa Antibiotic Resistance Market, by Disease
    - Complicated Urinary Tract Infection (cUTI)
    - Complicated Intra-Abdominal Infections (cIAI)
    - Blood Stream Infections (BSI)
    - Clostridium difficile infections (CDI)
    - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
    - Community Acquired Bacterial Pneumonia (CABP)
  - Middle East and Africa Antibiotic Resistance Market, by Pathogen
    - Acinetobacter baumannii (Carbapenem-Resistant)
    - Staphylococcus Aureus (Methicillin-Resistant)
    - Pseudomonas aeruginosa (Carbapenem-Resistant)
    - E. coli/K. pneumoniae (Carbapenem-Resistant)
    - Enterococcus faecium (Vancomycin-Resistant)
    - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
    - Haemophilus Influenzae (Ampicillin-Resistant)
    - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
  - Middle East and Africa Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Cephalosporins
    - Combination
    - Others
  - South Africa
    - South Africa Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - South Africa Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - South Africa Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Saudi Arabia
    - Saudi Arabia Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Saudi Arabia Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Saudi Arabia Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - Turkey
    - Turkey Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - Turkey Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - Turkey Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others
  - U.A.E.
    - U.A.E. Antibiotic Resistance Market, by Disease
      - Complicated Urinary Tract Infection (cUTI)
      - Complicated Intra-Abdominal Infections (cIAI)
      - Blood Stream Infections (BSI)
      - Clostridium difficile infections (CDI)
      - Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      - Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
      - Community Acquired Bacterial Pneumonia (CABP)
    - U.A.E. Antibiotic Resistance Market, by Pathogen
      - Acinetobacter baumannii (Carbapenem-Resistant)
      - Staphylococcus Aureus (Methicillin-Resistant)
      - Pseudomonas aeruginosa (Carbapenem-Resistant)
      - E. coli/K. pneumoniae (Carbapenem-Resistant)
      - Enterococcus faecium (Vancomycin-Resistant)
      - Streptococcus pneumoniae (Penicillin-Non-Susceptible)
      - Haemophilus Influenzae (Ampicillin-Resistant)
      - Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
    - U.A.E. Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Cephalosporins
      - Combination
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2014 to 2025
Market estimates and forecast for product segments up to 2025
Regional market size and forecast for product segments up to 2025
Market estimates and forecast for application segments up to 2025
Regional market size and forecast for application segments up to 2025
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.